Current use of benzodiazepines in anxiety disorders
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The aim of this study is to provide a review of articles published between July 2007 and August 2008 on the current use and rationale of benzodiazepines in anxiety disorders. RECENT FINDINGS: Recent review articles confirm selective serotonin reuptake inhibitors as first-choice drugs for treating anxiety disorders, alongside newer agents such as pregabalin or serotonin-norepinephrine reuptake inhibitors, and combined with cognitive-behavioural therapy. Benzodiazepines are still widely used by clinicians for these disorders, as shown by recent surveys, even though their anxiolytic effectiveness is questioned. Newer agents are in development and may in the future resolve the therapeutic dilemma. SUMMARY: Despite current guidelines, benzodiazepines are still considered by many clinicians to remain good treatment options, in both the acute and the chronic phase of the treatment of anxiety disorders, partially because of their rapid onset of action and their efficacy with a favourable side effect profile, and also because of the sometimes only incomplete therapeutic response and the emergence of side effects of alternative medications. Having experienced good initial symptom relief with benzodiazepine treatment, patients may also be reluctant to taper it down. Clinicians should, however, bear in mind the frequent physiological dependence associated with these substances, and suggest both pharmacological and psychological treatment alternatives before opting for a long-term benzodiazepine treatment, which may remain necessary in certain clinical conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Existing treatments for anxiety disorders are inconsistently effective or associated with significant adverse effects5, 7”
From Evolutionarily conserved prefrontal-amygdalar dysfunction in early-life anxiety (2014) · cites this paper as [7]
Citations
Cites
Hoffman, S. G., & Smits, J. A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0415 · Cited by 1,420
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
Hidalgo, R. B., Tupler, L. A., & Davidson, J. R. T. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107076996 · Cited by 177
ECT, Research, and Professional Ambivalence
Salzman, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.1 · Cited by 175
Clinical factors influencing the prescription of antidepressants and benzodiazepines:
Demyttenaere, K., Bonnewyn, A., Bruffaerts, R., de Girolamo, G., Gasquet, I., Kovess–Masféty, V., Haro, J. M., & Alonso, J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.011 · Cited by 157
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Bierman, E. J. M., Comijs, H. C., Gundy, C. M., Sonnenberg, C., Jonker, C., & Beekman, A. T. F. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1811 · Cited by 114
Cook, J. M., Biyanova, T., Masci, C., & Coyne, J. C. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0205-5 · Cited by 107
Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review
Dunlop, B. W., & Davis, P. G. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0307 · Cited by 106
Martin, J. L. R., Sainz-Pardo, M., Furukawa, T. A., Martin-Sanchez, E., Seoane, T., & Galan, C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077355 · Cited by 103
Altamura, A. C., Dell'Osso, B., D'Urso, N., Russo, M., Fumagalli, S., & Mundo, E. (2008) · CNS Spectrums · doi:10.1017/s1092852900016588 · Cited by 93
Research works printed but not linked: 5
- Dailly, 2008, Pak J Pharm Sci, 21, 144
- Sim, 2007, Aust Fam Physician, 36, 923
- Chen, 2008, IDrugs, 11, 189
- Cortés-Cortés, 2007, Proc West Pharmacol Soc, 50, 87
- Atack, 2008, CNS Neurosci Ther, 14, 25, 10.1111/j.1755-5949.2007.00034.x · doi:10.1111/j.1755-5949.2007.00034.x · Paper page
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
“Thus, despite current guidelines, many clinicians still regard BZDs as acceptable treatment options, both in the acute and the chronic phases of the treatment of anxiety disorders, partially because of their rapid onset of action and their efficacy with a favourable side effect profile, and also because of the sometim…”
BackgroundHydroxyzine for generalised anxiety disorder
Guaiana, G., Barbui, C., & Cipriani, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006815.pub2 · Cited by 272
Orexin, stress, and anxiety/panic states
Johnson, P. L., Molosh, A., Fitz, S. D., Truitt, W. A., & Shekhar, A. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-59489-1.00009-4 · Cited by 216
“Furthermore, benzodiazepines which are the most effective panicolytic treatment (Baldwin et al., 2005; Bandelow et al., 2008; Cloos and Ferreira, 2009; Nutt et al., 2002), restores GABAergic inhibition (Goddard et al., 2004).”
BackgroundMethodInfluentialEvidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
Ipser, J. C., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001209 · Cited by 216
“No evidence of efficacy was available for benzodiazepines, despite their continued popularity in clinical practice (Cloos & Ferreira, 2009).”
BackgroundDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
“[34].”
Metadata
- Authors
- Cloos, J.-M., & Ferreira, V.
- Corresponding author
- Cloos, Jean-Marc
- ORCID
- Cloos, Jean-Marc
- Venue
- Current Opinion in Psychiatry
- Published
- 2009-01
- Volume
- 22
- Issue
- 1
- Pages
- 90-95
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W1971911881
- Cited by
- 127
- References
- 30
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 10 · 2019: 9 · 2018: 5 · 2017: 9 · 2016: 8 · 2015: 3 · 2014: 8 · 2013: 7 · 2012: 14
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- benzodiazepines, anxiety disorders, anxiolytic treatment, selective serotonin reuptake inhibitors, pregabalin, serotonin-norepinephrine reuptake inhibitors, cognitive behavioral therapy, benzodiazepine dependence, long-term benzodiazepine use
- MeSH terms
- Antidepressive Agents, Anxiety Disorders, Benzodiazepines, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current use of benzodiazepines in anxiety disorders. https://app.cochat.ai/papers/10.1097/yco.0b013e32831a473d
- The paper
- Cloos, J.-M., & Ferreira, V. (2009). Current use of benzodiazepines in anxiety disorders. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e32831a473d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.